Vaqta™

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline, Merck Sharp & Dohme LLC

Conditions

Hepatitis AHepatitis BPneumococcal InfectionsPneumococcal Vaccines

Phase 3

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

CompletedNCT03893448

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines

Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Phase 4

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

CompletedNCT00289731

GlaxoSmithKlineHepatitis A, Hepatitis B

Start: 2003-11-24End: 2004-12-21Updated: 2019-11-15

Related Papers

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Expert Review of Vaccines2023-10-176 citations

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Vaccine2023-01-0141 citations